Literature DB >> 15799863

Absorbed dose estimates at the cellular level for 131I.

Perihan Unak1, Berkan Cetinkaya.   

Abstract

Microdosimetric calculations of 131I have been evaluated for a single cell and for cell clusters. A VsBasic program has been used to calculate stopping power, linear energy transfer, range values and deposited energies per decay for beta particles, Auger and conversion electrons of 131I. The chemical composition of the cell has been taken into account in this model; results were compared with water medium. Besides, total absorbed doses have been calculated for the radionuclides distributed randomly within the cell and clusters. Cross-fire irradiation has been considered for clusters of cells. In this case, absorbed doses per cell within a cluster were found to be significantly higher than absorbed doses per single cell, depending on the cluster size. Results showed that 131I is a promising radionuclide for therapy of tumors from millimeter to centimeter dimensions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15799863     DOI: 10.1016/j.apradiso.2004.07.013

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  4 in total

1.  Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma.

Authors:  Ferdinand Sudbrock; Matthias Schmidt; Thorsten Simon; Wolfgang Eschner; Frank Berthold; Harald Schicha
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-24       Impact factor: 9.236

2.  Relative Biological Effectiveness (RBE) of (131)I Radiation Relative to (60)Co Gamma Rays.

Authors:  Ali Neshasteh-Riz; Ali Mahmoud Pashazadeh; Seyed Rabie Mahdavi
Journal:  Cell J       Date:  2013-08-24       Impact factor: 2.479

3.  131I-Traced PLGA-Lipid Nanoparticles as Drug Delivery Carriers for the Targeted Chemotherapeutic Treatment of Melanoma.

Authors:  Haiyan Wang; Weizhong Sheng
Journal:  Nanoscale Res Lett       Date:  2017-05-19       Impact factor: 4.703

4.  Thymoquinone Glucuronide Conjugated Magnetic Nanoparticle for Bimodal Imaging and Treatment of Cancer as a Novel Theranostic Platform.

Authors:  İskender İnce; Zümrüt Biber Müftüler; E İlker Medine; Özge Kozguş Güldü; Gökhan Takan; Ayşegül Ergönül; Yasemin Parlak; Yeliz Yıldırım; Burcu Çakar; Elvan Sayit Bilgin; Ömer Aras; Erdem Göker; Perihan Ünak
Journal:  Curr Radiopharm       Date:  2021
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.